Overview

• U.S. regulators cleared Wegovy for treating MASH in adults with moderate-to-advanced liver fibrosis, making it the first GLP-1 approved for this condition.
• Novo Nordisk set Ozempic at $499 per month for U.S. patients without insurance, down from about $1,000, while noting roughly 98% of users are insured and typically pay $25 or less.
• Ozempic will be offered with home delivery through NovoCare for the first time, and both Ozempic and Wegovy will be available directly via GoodRx.
• Shares of Novo Nordisk rose about 6–7% in Copenhagen trading following the approval and pricing moves, and GoodRx jumped 35% on the partnership news.
• Competitive pressure is intensifying, with Dr Reddy's saying it plans to launch a lower-cost semaglutide in 87 countries next year and Eli Lilly vying in the same market.